-47%

est. 2Y upside i

HealthcareSeries D+

Rank

#2704

Sector

Biotechnology

Est. Liquidity

~2Y

Data Quality

Data: Medium

eGenesis presents a moderate upside opportunity for a job seeker, with an estimated 32% expected upside over a two-year horizon.

Last updated: March 10, 2026

Bull (30%)+100%

eGenesis successfully advances its lead kidney transplant program (EGEN-2784) through pivotal clinical trials, demonstrating superior long-term outcomes and securing accelerated regulatory approval. This validates the EGEN™ Platform, attracting major pharmaceutical partnerships and driving a $3.0B+ valuation, representing a 2x increase from the current estimate.

Base (50%)+20%

eGenesis continues to make steady progress in clinical development, achieving key milestones for EGEN-2784 and expanding its pipeline. While facing competition, the company maintains its leadership in xenotransplantation, leading to a modest valuation increase to approximately $1.8B through continued private funding or a conservative IPO.

Bear (20%)-40%

Clinical trials encounter unexpected setbacks, or a competitor like United Therapeutics gains a significant lead in regulatory approvals or market adoption. This leads to a down round or a significantly lower-than-expected exit valuation of around $0.9B, severely impacting common stock value due to existing liquidation preferences.

Est. time to liquidity~2.0 years

Preference Stack Risk

severe

Investors hold $454M in liquidation preferences, meaning common shareholders would only see returns on value above this amount, assuming a current valuation of $1.5B.

Dilution Risk

high

Further funding rounds are highly probable to advance clinical trials and scale operations, leading to additional dilution for existing equity holders.

Secondary Liquidity

none

There is no active secondary market or tender offer program indicated, meaning equity is illiquid until an IPO or acquisition.

Technical Operations — 4 roles

Quality — 3 roles

Clinical Development — 1 role

Regulatory Affairs — 1 role

View all 9 open roles at Egenesisbio →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on Egenesisbio's data — designed to show you've done your homework.

  • 1

    “Given that United Therapeutics has also received FDA clearance for its UKidney clinical trial, how does eGenesis differentiate its technology and clinical strategy to maintain its competitive edge in the xenotransplantation market?”

  • 2

    “With the significant capital intensity of developing genetically engineered organs, how does eGenesis plan to manage its burn rate and secure future funding rounds, especially considering the current severe preference stack for existing investors?”

  • 3

    “Considering the positive clinical milestones and the mention of an IPO, what is the realistic timeline and key milestones the company is targeting for a liquidity event for employees holding equity?”

Community

Valuation Sentiment

Our model estimates -47% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.